Administration, Intravesical: The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Urinary Bladder: A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION.BCG Vaccine: An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.Cystitis: Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.Cystoscopy: Endoscopic examination, therapy or surgery of the urinary bladder.Urinary Bladder Diseases: Pathological processes of the URINARY BLADDER.Cystitis, Interstitial: A condition with recurring discomfort or pain in the URINARY BLADDER and the surrounding pelvic region without an identifiable disease. Severity of pain in interstitial cystitis varies greatly and often is accompanied by increased urination frequency and urgency.Urination: Discharge of URINE, liquid waste processed by the KIDNEY, from the body.Administration, Oral: The giving of drugs, chemicals, or other substances by mouth.Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.Urinary Bladder, Neurogenic: Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES.Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.Urodynamics: The mechanical laws of fluid dynamics as they apply to urine transport.Mandelic Acids: Analogs or derivatives of mandelic acid (alpha-hydroxybenzeneacetic acid).Ureter: One of a pair of thick-walled tubes that transports urine from the KIDNEY PELVIS to the URINARY BLADDER.Urinary Bladder, Overactive: Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.Cystotomy: Surgical incision or puncture into a URINARY BLADDER. Cystotomy may be used to remove URINARY CALCULI, or to perform tissue repair and reconstruction.Urothelium: The epithelial lining of the URINARY TRACT.Cystectomy: Used for excision of the urinary bladder.Mycobacterium bovis: The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis.Tuberculosis, Cardiovascular: Pathological conditions of the CARDIOVASCULAR SYSTEM caused by infection of MYCOBACTERIUM TUBERCULOSIS. Tuberculosis involvement may include the HEART; the BLOOD VESSELS; or the PERICARDIUM.Urinary Bladder Neck Obstruction: Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Rats, Sprague-Dawley: A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.Ureteral Neoplasms: Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.Immunotherapy: Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.Antibiotics, Antineoplastic: Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.Tuberculosis, Male Genital: MYCOBACTERIUM infections of the male reproductive tract (GENITALIA, MALE).Reflex, Abnormal: An abnormal response to a stimulus applied to the sensory components of the nervous system. This may take the form of increased, decreased, or absent reflexes.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Urethra: A tube that transports URINE from the URINARY BLADDER to the outside of the body in both the sexes. It also has a reproductive function in the male by providing a passage for SPERM.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Urologic Surgical Procedures: Surgery performed on the urinary tract or its parts in the male or female. For surgery of the male genitalia, UROLOGIC SURGICAL PROCEDURES, MALE is available.Adjuvants, Immunologic: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.Prostatism: Lower urinary tract symptom, such as slow urinary stream, associated with PROSTATIC HYPERPLASIA in older men.Injections, Intravenous: Injections made into a vein for therapeutic or experimental purposes.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.United States Food and Drug Administration: An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.Urination Disorders: Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.Reflex: An involuntary movement or exercise of function in a part, excited in response to a stimulus applied to the periphery and transmitted to the brain or spinal cord.Rats, Wistar: A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.Neuromuscular Agents: Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.Drug Administration Routes: The various ways of administering a drug or other chemical to a site in a patient or animal from where the chemical is absorbed into the blood and delivered to the target tissue.Hyperthermia, Induced: Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.Botulinum Toxins, Type A: A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25.Mice, Inbred C57BLPentosan Sulfuric Polyester: A sulfated pentosyl polysaccharide with heparin-like properties.Hypogastric Plexus: A complex network of nerve fibers in the pelvic region. The hypogastric plexus distributes sympathetic fibers from the lumbar paravertebral ganglia and the aortic plexus, parasympathetic fibers from the pelvic nerve, and visceral afferents. The bilateral pelvic plexus is in its lateral extent.AcroleinUrinary Catheterization: Passage of a CATHETER into the URINARY BLADDER or kidney.Urologic Neoplasms: Tumors or cancer of the URINARY TRACT in either the male or the female.Aneurysm, Infected: Aneurysm due to growth of microorganisms in the arterial wall, or infection arising within preexisting arteriosclerotic aneurysms.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Antimetabolites, Antineoplastic: Antimetabolites that are useful in cancer chemotherapy.Parasympatholytics: Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.Urine: Liquid by-product of excretion produced in the kidneys, temporarily stored in the bladder until discharge through the URETHRA.Administration, Intranasal: Delivery of medications through the nasal mucosa.Capsaicin: An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS.Mitomycins: A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.Neurons, Efferent: Neurons which send impulses peripherally to activate muscles or secretory cells.Pressure: A type of stress exerted uniformly in all directions. Its measure is the force exerted per unit area. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)DeoxycytidineUrinary Bladder Calculi: Stones in the URINARY BLADDER; also known as vesical calculi, bladder stones, or cystoliths.Neurons, Afferent: Neurons which conduct NERVE IMPULSES to the CENTRAL NERVOUS SYSTEM.Mucous Membrane: An EPITHELIUM with MUCUS-secreting cells, such as GOBLET CELLS. It forms the lining of many body cavities, such as the DIGESTIVE TRACT, the RESPIRATORY TRACT, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose CONNECTIVE TISSUE, and an outer layer (muscularis mucosae) of SMOOTH MUSCLE CELLS that separates the mucosa from submucosa.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Urinary Tract: The duct which coveys URINE from the pelvis of the KIDNEY through the URETERS, BLADDER, and URETHRA.Injections, Intraperitoneal: Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall.Vesico-Ureteral Reflux: Retrograde flow of urine from the URINARY BLADDER into the URETER. This is often due to incompetence of the vesicoureteral valve leading to ascending bacterial infection into the KIDNEY.Mice, Inbred C3HMuscle Contraction: A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.Kidney Pelvis: The flattened, funnel-shaped expansion connecting the URETER to the KIDNEY CALICES.Pelvis: The space or compartment surrounded by the pelvic girdle (bony pelvis). It is subdivided into the greater pelvis and LESSER PELVIS. The pelvic girdle is formed by the PELVIC BONES and SACRUM.Rats, Inbred F344Muscarinic Antagonists: Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients. (1/242)

We investigated the potential existence of differences in the distribution of T-lymphocyte subsets and in the proliferative response of these CD2+ cells to polyclonal mitogens in patients with transitional cell bladder carcinoma (SBTCC) treated with prophylactic intracavitary instillations of bacillus Calmette-Guerin (BCG) according to their clinical response to this treatment. Before BCG treatment, different subset distribution (CD8+ and CD3+ CD56+), activation antigen expression (CD3+ HLA- DR+) and proliferative response to mitogenic signals were found in CD2+ cells from SBTCC patients prophylactically treated with BCG who remained free of disease or those who had recurrence of tumour. Otherwise, the prophylactic intracavitary BCG instillations in SBTCC patients are associated with a transitory variation of T-lymphocyte subset distribution (CD4 and CD8) and activation antigens expression (CD25).  (+info)

Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. (2/242)

We report a case of Mycobacterium bovis BCG vertebral osteomyelitis in a 79-year-old man 2.5 years after intravesical BCG therapy for bladder cancer. The recovered isolate resembled M. tuberculosis biochemically, but resistance to pyrazinamide (PZA) rendered that diagnosis suspect. High-pressure liquid chromatographic studies confirmed the diagnosis of M. bovis BCG infection. The patient was originally started on a four-drug antituberculous regimen of isoniazid, rifampin, ethambutol, and PZA. When susceptibility studies were reported, the regimen was changed to isoniazid and rifampin for 12 months. Subsequently, the patient was transferred to a skilled nursing facility for 3 months, where he underwent intensive physical therapy. Although extravesical adverse reactions are rare, clinicians and clinical microbiologists need to be aware of the possibility of disseminated infection by M. bovis BCG in the appropriate setting of clinical history, physical examination, and laboratory investigation.  (+info)

Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. (3/242)

More active and well-tolerated agents are needed for the treatment of superficial bladder cancer. This study investigated intravesical gemcitabine to establish the toxicology and pharmacokinetics necessary for clinical trials. Beagle dogs (in groups of 2; n = 6) received 100 mg, 350 mg, or 1 g of drug by intravesical administration on alternate days three times/week for 4 weeks. Animals were observed for clinical signs of toxicity; gemcitabine levels and peripheral blood counts were taken three times weekly. The dogs were euthanized, and a full necropsy was performed at days 1 and 14 after the last dose. Intravesical gemcitabine was given at 100 mg (n = 2), 350 mg (equivalent to the 1000 mg/m2 human dose; n = 3), and 3.5 g (n = 1). i.v. gemcitabine was given at 350 mg (n = 2). Plasma samples drawn at time points up to 8 h were analyzed for systemic absorption and clearance of drug. Doses of 100 and 350 mg were well tolerated with no clinical side effects. Necropsies revealed normal bone marrow cellularity and normal bladder histology. At 1 g, signs of severe clinical toxicity were evident, and after only three doses, necropsies demonstrated severe bone marrow hypoplasia, cystitis, and intestinal necrosis. At all intravesical doses, significant systemic absorption was seen. The T1/2 (+/- SD) for intravesical and i.v. administration of 350 mg was 328 (+/-6.8) min and 99.3 (+/-5.2) min, respectively (P<0.001). Intravesical gemcitabine is well tolerated and has no direct bladder toxicity at doses up to 1000 mg/m2. Higher doses result in gastrointestinal, bladder, and bone marrow toxicity.  (+info)

Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. (4/242)

Although Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been accepted as the most effective agent in clinical use against superficial bladder cancer, its mechanism of action remains incompletely understood. A kinetic analysis in assessing the potential role of cytokines from BCG-stimulated murine splenocytes showed that IL-12 expression preceded that of other cytokines. Experiments subtracting endogenous BCG-driven IL-12 using neutralizing Ab or augmenting its activity with supplemental rIL-12 revealed not only that IL-12 plays a dominant role in IFN-gamma induction but also that it is normally dose limiting. A striking increase in IFN-gamma production could be generated in both mouse and human immunocompetent cell culture by the addition of even a small amount of rIL-12. Moreover, this same synergistic effect could be replicated during in vivo administration of BCG plus rIL-12 into the mouse bladder and was observed in a patient receiving intravesical combination therapy. In costimulation cultures, this synergy appeared to partially rely on IL-18 and IL-2 and could be down-regulated by IL-10. This suggests that a dynamic interplay between Th1 and Th2 cytokines is responsible for net IFN-gamma production. The ability of supplemental exogenous IL-12 to strongly shift this balance toward Th1 provides an immunological basis for using it in conjunction with intravesical BCG for bladder cancer immunotherapy.  (+info)

Primary lymphoma of the bladder treated successfully with mitozantrone gel. (5/242)

We describe a young man who presented with a short history of painless haematuria. Subsequent investigations and biopsy of lesions found in his bladder at cystoscopy confirmed the diagnosis of primary lymphoma of the bladder. Computed tomography studies confirmed the disease was localised to his bladder. Unfortunately, the tumour was not eradicated by radiotherapy. However, it was successfully treated with intravesical mitozantrone given in a novel gel formation. Three years after diagnosis the patient remains well with no evidence of recurrence.  (+info)

Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. (6/242)

PURPOSE: More effective intravesical agents are required to limit the recurrence and progression of superficial bladder cancer. This study assessed the ability of copper-67 ((67)Cu)-C595 murine antimucin monoclonal antibody to bind selectively to superficial bladder tumors when administered intravesically, with a view to its development for therapy. PATIENTS AND METHODS: Approximately 20 MBq of (67)Cu-C595 monoclonal antibody was administered intravesically to 16 patients with a clinical indication of superficial bladder cancer. After 1 hour, the bladder was drained and irrigated. Tissue uptake was assessed by imaging and by the assay of tumor and normal tissues obtained by endoscopic resection. RESULTS: Tumor was correctly identified in the images of 12 of 15 patients who were subsequently found to have tumors. Assay of biopsy samples at 2 hours showed a mean tumor uptake of 59.4% of the injected dose per kilogram (SD = 48.0), with a tumor-to-normal tissue ratio of 14.6:1 (SD = 20). After 24 hours (n = 5), this decreased to 4.3% of the injected dose per kilogram (SD = 2.9), with a tumor-to-normal tissue ratio of 1.8:1 (SD = 0.8). CONCLUSION: This study indicates a promising method for the treatment of superficial bladder cancer. Although the mean initial tumor uptake was high, effective therapy of bladder tumors will require an increased retention of the cytotoxic radionuclide in tumor tissue.  (+info)

Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. (7/242)

Using a novel orthotopic MBT-2 murine bladder tumor model, we evaluated the feasibility of intravesical gene therapy utilizing a cationic liposome, DMRIE/DOPE. Superficial bladder tumors were consistently established by intravesical instillation of 5x10(5) MBT-2 cells in syngeneic C3H female mice. In situ gene transfer to bladder tumors was accomplished via intravesical instillation of plasmid DNA/DMRIE/DOPE lipoplex. Beta-Galactosidase (beta-gal) gene expression was preferentially evident in bladder tumors and was present for at least 7 days after a single 30 min in situ transfection. Murine interleukin-2 (IL-2) gene was used for treatment of 3-day-old pre-established bladder tumors. Forty percent of animals treated with IL-2 gene were completely free of tumors by 60 days following the initial tumor implantation, while all control groups treated with beta-gal gene died. Those animals initially cured of pre-established tumors were completely resistant to a subsequent tumor re-challenge and their splenocyte-derived cytotoxic T lymphocytes were shown to be specific to MBT-2 cells, indicating that immunological memory against MBT-2 tumors was elicited by the treatment. These results demonstrate the possibility of an effective clinical application of this in situ intravesical IL-2 gene delivery system to high-risk superficial bladder tumors, obviating a need for tumor procurement and ex vivo gene transfer.  (+info)

Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. (8/242)

The local immune response to mycobacteria is complex, but mycobacterial antigen presentation by phagocytes to T helper cells is the pivotal interaction. Bacille Calmette-Guerin (BCG) vaccination is associated with the development of antituberculosis immunity but not necessarily with antitumor immunity. Animal studies have shown that an intact host immune system is required for the antitumor activity of BCG. Immunosuppressed and, particularly, T cell-depleted individuals fail to respond to BCG immunotherapy. Clinical and laboratory evidence suggest that the antitumor activity is concentrated at the site of BCG administration, which reinforces the view that local immune mechanisms are responsible for this phenomenon.  (+info)

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer Academic Article ...
Clinical Application of the Adenosine Triphosphate-based Response Assay in Intravesical Chemotherapy for Superficial Bladder Cancer Adenosine triphosphate;chemotherapy response assay;superficial bladder cancer; Objective: To investigate correlations between adenosine triphosphate chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-based chemotherapy for drug selection in patients receiving intravesical chemotherapy to prevent recurrence of superficial bladder cancer after surgery. Methods: The chemosensitivities of 12 anticancer drugs were evaluated, including 5-Fu ADM, and EPI, using ATP-CRA and primary tumor cell culture in 54 patients. In addition, a further 58 patients were treated according to clinical experience. Differences in post-chemotherapeutical effects between drug sensitivity assay and experience groups were compared. Results: The evaluable rate of the test was 96.3%, the clinical effective rate was 80.8%, the sensitivity rate was 97.6% (41/42), the specificity was
Request a copy of Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer., a 21st Century Oncology physician publication.
Bladder cancer is the fourth and eighth most common malignancy among men and women, respectively. About 75% of bladder cancers are diagnosed as non muscle-invasive and according to specific tumor-stage and grade characteristics, intravesical immunotherapy with Bacillus Calmette-Guérin (BCG) is used to prevent recurrence and/or progression. However, BCG immunotherapy is associated with significant adverse events and treatment failure may occur in 30-40% of cases, hence the necessity for alternative therapies. In an orthotopic MB49 mouse bladder cancer model, another bacterial vaccine (Ty21a/Vivotif) turned out to be more effective than BCG for inducing tumor regression and mice survival upon intravesical instillation; and potentially safer because Ty21a bacteria did not infect/persist in any mice tissues nor in human bladder explants or cell lines, in contrast to BCG. Ty21a/Vivotif has been used in the last 30 years in millions of individuals as an oral typhoid vaccine with a high safety record. ...
Non-muscle-Invasive Bladder cancer is mainly treated by tumor resection (Trans Urethral Resection - TUR), followed by series of intravesical instillations of prophylactic chemotherapeutic drugs as Mitomycin C (MMC).This treatment approach is limited due to rapid dilution the chemotheraputic drug by the incoming urine and clearance by urination.. TheraCoat core technology is based on a reverse thermal (low viscosity at 5°C) degradable gel (TC-3)for MMC retention in the urinary bladder.. Prior to instillation, the TC-3 hydrogel,in a liquid state, is mixed with MMC.TC-3 mixed with MMC is instilled to the bladder by a catheter.Following gel insertion to the bladder, the gel solidifies and forms a drug reservoir inside the bladder. Upon contact with urine the gel dissolves and is cleared out from the bladder.. Intravesical MMC using TheraCoat gel is expected to increase treatment efficiency due to prolongation of treatment duration and consequently improving bladder exposure to MMC. ...
Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive bladder cancer. Primary producers of BCG announced shortages within the last decade, leading to a worldwide shortage. We review the literature examining the BCG shortage and propose solutions to cope with this problem.
Find the best intravesical chemotherapy doctors in Delhi NCR. Get guidance from medical experts to select intravesical chemotherapy specialist in Delhi NCR from trusted hospitals - credihealth.com
In this preliminary study, bladder instillations of HA had a significant effect on the rate of UTI in women with a history of recurrent UTIs. The bladder instillation of HA is an acceptable and promising therapeutic alternative in patients with recurrent UTI. Expanded placebo controlled clinical tri …
Intravesical administration of the cytotoxic drug doxorubicin is a common treatment for superficial carcinoma of the bladder, but it is associated with significant urological adverse effects. The aim of this study was to identify doxorubicin-induced changes in the local mechanisms involved in regulating bladder function. As a model of intravesical doxorubicin administration in patients, doxorubicin (1 mg/mL) was applied to the luminal surface of porcine bladders for 60 min. Following treatment, the release of urothelial/lamina propria mediators (acetylcholine (Ach), ATP and prostaglandin E2 (PGE2) and contractile responses of isolated tissue strips was investigated. Doxorubicin pretreatment did not affect contractile responses of detrusor muscle to carbachol, but did enhance neurogenic detrusor responses to electrical field stimulation (219 % at 5 Hz). Contractions of isolated strips of urothelium/lamina propria to carbachol were also enhanced (30 %) in tissues from doxorubicin pretreated bladders.
Intravesical treatment of superficial bladder cancer is done to prevent tumor recurrence after successful local surgical resection and to eradicate residual disease. Various intravesical chemotherapeutic agents, such as thiotepa, doxorubicin, and mitomycin, have been the therapeutic treatment of choice for years; however, these agents achieved short remissions with a net durable benefit for ∼7% to 14% of patients ( 26). More unconventional forms of treatment, such as immunotherapy, were introduced in the last few decades due to unsatisfactory chemotherapy results, where one of the most successful therapies for superficial bladder cancer and carcinoma in situ of the bladder is intravesical administration of Mycobacterium bovis bacillus Calmette-Guerin (BCG; ref. 27). However, this therapy has also displayed limited success because 25% to 40% of the patients never respond to BCG ( 28, 29). The development of therapeutic regimens that offer potent tumoricidal activity but no toxic side effects to ...
A look at the following clinical trial: Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) (NMIBC TURBT HG).
Long-term results were analyzed in terms of tumor progression and survival in patients with superficial bladder cancer who were enrolled in the second intravesical chemoprophylactic study of the...
Intravesical therapy is a treatment that is put directly into the bladder (through a catheter) rather than being given by mouth or injected into a vein.
Intravesical BCG Treatment   BCG placed into the bladder following the diagnosis of bladder cancer has been shown to decrease the rate of tumour recurrence but more importantly it decreases the rate of tumour progression - ie: it can prevent a superficial cancer from turning into a more serio
TY - JOUR. T1 - Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. AU - Kluth, Luis A.. AU - Xylinas, Evanguelos. AU - Crivelli, Joseph J.. AU - Passoni, Niccolo. AU - Comploj, Evi. AU - Pycha, Armin. AU - Chrystal, James. AU - Sun, Maxine. AU - Karakiewicz, Pierre I.. AU - Gontero, Paolo. AU - Lotan, Yair. AU - Chun, Felix K H. AU - Fisch, Margit. AU - Scherr, Douglas S.. AU - Shariat, Shahrokh F.. PY - 2013/8. Y1 - 2013/8. N2 - Purpose: To our knowledge the impact of body mass index on oncologic outcomes in nonmuscle invasive bladder cancer has not been evaluated. We hypothesized that higher body mass index is associated with worse outcomes in patients with clinical primary T1 high grade urothelial carcinoma of the bladder. Materials and Methods: We retrospectively analyzed data from 892 patients with primary nonmuscle invasive bladder cancer from 7 centers. Patients were treated with transurethral resection of the bladder with or ...
P.I.: Satia, Jessie A Department: Nutrition and Epidemiology Title: Effect of Supplemental Omega-3 Fatty Acids in Patients with Superficial Bladder Cancer After Transurethral Resection: A Randomized Trial
Barmoshe S, et al. (2004). Prognosis of T1G3 tumors: clinical factors. Eur Urol Suppl. 3:73-8. Bernini L, et al (2013). Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature. Autoimmun Rev. 12(12):1150-1159 Brausi M, et al. (2014). Side effects of bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 65(1):69-76. Decaestecker K, et al. (2015). Managing the adverse events of intravesical bacillus Calmette-Guérin therapy. Res Rep Urol. 7: 157-163. Herr HW, et al (1989). Superficial bladder cancer treated with bacillus Calmette-Guérin: A multivariate analysis of factors affecting tumor progression. J Urol. 141:22-9 Hogarth M B, et al. (2000). Reiters syndrome following ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohm RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000; 163: 1124-9 ...
TY - JOUR. T1 - Diagnosis and management of superficial bladder cancer. AU - Soloway, M. S.. PY - 1989/1/1. Y1 - 1989/1/1. UR - http://www.scopus.com/inward/record.url?scp=0024435009&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0024435009&partnerID=8YFLogxK. M3 - Article. C2 - 2549605. AN - SCOPUS:0024435009. VL - 5. SP - 247. EP - 254. JO - Journal of Surgical Oncology. JF - Journal of Surgical Oncology. SN - 0022-4790. IS - 4. ER - ...
New chemotherapeutic agents undergoing evaluation in prospective clinical trials include vinflunine, ixabepilone as well as others. 3. Immunotherapy for patients with metastatic or unresectable bladder cancer The role of immunotherapy has long been established in non-muscle-invasive bladder cancer. The localized inflammatory response to intravesical BCG appears to be the source of its anti-tumor activity. For advanced or metastatic urothelial carcinomas, there is now an established role for immune checkpoint inhibitors. Currently, 5 antibodies targeting the PD1/PD-L1 axis are FDA approved for this indication. The PD-1 inhibitor pembrolizumab is approved for the treatment of patients with advanced or metastatic urothelial carcinomas who have progressed on or following prior platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. This approval is based on improved overall survival (OS) with pembrolizumab compared to cytotoxic chemotherapy. ...
The ability of the immune system to recognize and eradicate cancer was first postulated in the 19th century; however, proof of principle remained elusive until the 20th century. The effect of infection on tumor regression was observed as early as 1884 by Anton Chekov (1); following this, William Coley developed a mixture of killed bacteria that were used to treat various types of cancer between the 1890s and 1960s with mixed clinical benefit. In addition, the concept of using bacterial elements was validated with Food and Drug Administration (FDA) approval of intravesical administration of BCG, which is an FDA-approved therapy that leads to nonspecific inflammatory immune responses and clinical benefit for patients with superficial bladder cancer (2). The discovery of the major histocompatibility complex (MHC) and T-cell receptor (TCR) in the 1980s provided insight into T-cell function that led to a number of clinical trials (3,4). Unfortunately, many of the early clinical trials failed due to ...
Increase in bladder mucosal permeability can be reproduced by intravesical administration of protamine sulfate (PS); however, the influence of PS once administered into the bladder disappears within several days. We developed a chronic animal model of urothelial injury using PS. Insertion of a polyethylene catheter through the bladder dome was performed in female Wistar rats. The other end of the catheter was connected to an osmotic pump for continuous delivery of PS or vehicle for 2 wk. Urinary frequency (UF) and voided volume (VV) were measured in the metabolic cage. The fifth group of rats received a high dose of PS (10 mg/ml) for 2 wk and were followed for a further 2 wk without PS. The sixth group received a high dose of PS for 2 wk and loxoprofen (0.1 mg.kg(-1).day(-1)) for 4 wk. UF was increased, and VV was reduced in rats treated with a high dose of PS but not changed in rats treated with a vehicle or a low dose of PS (1 mg/ml). UF was further increased in the fifth group, while unchanged in the
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting [email protected] All previous versions of the manuscript and all author responses to the reviewers are also available.. You can find further information about the peer review system here.. ...
TY - JOUR. T1 - Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. AU - Wheat, Jeffery C.. AU - Weizer, Alon Z.. AU - Wolf, J. Stuart. AU - Lotan, Yair. AU - Remzi, Mesut. AU - Margulis, Vitaly. AU - Wood, Christopher G.. AU - Montorsi, Francesco. AU - Roscigno, Marco. AU - Kikuchi, Eiji. AU - Zigeuner, Richard. AU - Langner, Cord. AU - Bolenz, Christian. AU - Koppie, Theresa M.. AU - Raman, Jay D.. AU - Fernández, Mario. AU - Karakiewizc, Pierre. AU - Capitanio, Umberto. AU - Bensalah, Karim. AU - Patard, Jean Jacques. AU - Shariat, Shahrokh F.. PY - 2012/5. Y1 - 2012/5. N2 - Objective: Carcinoma in situ (CIS) is associated with increased risk of progression when found with high-grade non-muscle-invasive bladder cancer, yet its impact is less clear in the upper urinary tract. In the current study, we evaluated the impact of concomitant CIS on recurrence-free survival and cancer-specific ...
People with intermediate-risk non-muscle-invasive bladder cancer should be offered a course of at least six doses of chemotherapy. The liquid is placed directly into your bladder, using a catheter, and kept there for around an hour before being drained away.. You should be offered follow-up appointments at three months, nine months, 18 months, then once every year. At these appointments, your bladder will be checked using a cystoscopy. If your cancer returns within five years, youll be referred back to a specialist urology team.. Some residue of the chemotherapy medication may be left in your urine after treatment, which could severely irritate your skin. It helps if you urinate while sitting down and that youre careful not to splash yourself or the toilet seat. After passing urine, wash the skin around your genitals with soap and water.. If youre sexually active, its important to use a barrier method of contraception, such as a condom. This is because the medication may be present in your ...
Background: Current treatment options for metastatic UC remain limited, and tolerability is a concern in many patients. Alterations in the fibroblast growth factor receptor (FGFR) pathway are implicated in development of non-muscle-invasive bladder cancer; FGFR3 mutations or FGFR translocations are present in ∼10-20% of patients with metastatic UC. Treatment with pan-FGFR (FGFR1-4) inhibitor JNJ-42756493 resulted in promising antitumor activity in a phase 1 trial in patients with advanced solid tumors, including 3 partial responses among 8 patients with UC (Tabernero J, et al. J Clin Oncol. 2015). Safety was manageable and as anticipated with a potent FGFR inhibitor. This phase 2 open-label study of JNJ-42756493 (NCT02365597) is being conducted to determine efficacy and safety of 2 different dose regimens in patients with metastatic or unresectable UC with specific FGFR translocations or mutations.. Methods: Eligible patients must have disease progression following chemotherapy for metastatic ...
BCG has been used as an antitumor agent for bladder cancer immunotherapy for over 2 decades (30). Although BCG antitumor activity has been clinically demonstrated, its successful use has been tempered by its systemic toxicity, unreliable efficacy, and prognostic unpredictability (4, 31). However, since BCG remains the most efficacious topical therapy for superficial bladder cancer, additional efforts to define an improved BCG regimen in both efficacy and safety should be pursued. Although the precise mechanism of BCG action remains to be defined, observations from both clinical and experimental studies suggest that BCG therapy requires an intact immune system, works via a localized process of stimulation, mediates an interacting network of immune cells and cytokines, and induces a nonspecific immune response (4, 31, 32, 33). As a potent immune stimulator, BCG elicits both humoral and cellular responses. However, antitumor immunity induced by intravesical BCG in bladder cancer therapy appears to ...
In this work, we present a novel use of an EGFR-directed fusion protein with a modified DT. Bladder cancer frequently overexpresses EGFR on the luminal surface, whereas such expression is uncommon on the normal urothelium. Using an orthotopic, xenograft model of bladder cancer, we showed a difference in the elimination of the implanted tumor after 2 weeks of intravesical treatment with DAB389EGF, as compared with the control DT chimeric protein (DAB388GM-CSF). Importantly, in immunocompetent mice, there was clear, generalized toxicity with the intravenous DAB389EGF treatment, but there was no evidence of histologic or generalized toxicity in the intravesically treated mice at equal doses.. While targeted agents have made significant inroads into the clinical management of most common cancer types, there is no integration of such agents into the routine treatment of urothelial carcinoma. Importantly, in most cases, the use of inhibiting a particular molecular pathway is dependent on "pathway ...
In vivo studies have been undertaken by several groups. The equipment used is generally less complicated than for the LIAFS studies, in that the fluorescence is assessed with a standard video camera, negating the need for a fluorescence detector. Some of the early studies used a photosensitizer (Photophrin™) to induce fluorescence [4], but more recent studies have used 5-ALA, hexyl-ALA or hypericin. The route by which the agent was administered has also varied. Some authors used systemic administration of the agent, hoping that the greater tumour penetration achieved would aid the assessment of adequate resection [11]. However, the systemic use of photosensitizers is limited by skin photosensitivity and thus most studies have used intravesical instillation of the agent, which obviates this problem. 5-ALA for use by the intravesical route must be prepared freshly each day and instilled 3 h before cystoscopy. Other than occasional reports of urgency or mild bladder discomfort, the intravesical ...
The purpose of the LMMG Lancashire Medicines Management Group is to provide a platform for a consensus decision making process relating to the use of medicines across the Lancashire NHS footprint, to ensure equity in access to medicines and optimisation of medicines use.
The most effective form of immunotherapy for solid tumours is still poorly understood. The main risks from superficial bladder cancer are that it may recur or that it may progress to invasive disease with a high mortality. Immunotherapy with live BCG vaccine was shown to be an effective treatment as long ago as 1976,1 and the vaccine is still the only intravesical agent to have been shown to reduce both of these risks.2. Factors that increase the risk of progression are high tumour grade, invasion of the lamina propria, and the presence of carcinoma in situ.3 The main indications for the use of BCG vaccine in Britain are treatment of carcinoma in situ of the bladder; treatment of residual superficial papillary tumour; and prophylaxis against recurrence of superficial tumours and against progression after resection of a tumour.. No one questions the use of BCG vaccine for diffuse carcinoma in situ. This condition is difficult to eradicate by resection--indeed, if treated by surgery alone it ...
The concept of using activation of the innate immune system and an inflammatory response against a bacterial component to instigate an antitumor response was studied in the 1960s, which led to the development of intravesical bacillus Calmette-Guérin, now used in the treatment of superficial bladder cancer. Over the following decades, the promise of immunotherapy ebbed and flowed until a couple of decades ago, when researchers saw promise in T-cell activation, paving the way for a revival of immunotherapy. Today, one of the most exciting areas in immunotherapy is checkpoint blockade.. The ASCO Post recently spoke with James P. Allison, PhD, who received the 2015 Lasker-DeBakey Clinical Medical Research Award for his pioneering work in enabling T cells to attack cancer cells by removing "checkpoints" that normally inhibit T-cell activity.. A Career-Changing Period. Please tell the readers a bit about your career and your current position.. I came from a small town in south Texas and received both ...
New intravesical treatment approaches for bladder cancer are needed as currently approved treatments show several side effects and high tumor recurrence rate. Our study used MB49 murine urothelial carcinoma model to evaluate oxygen encapsulated cellulosic nanobubbles as a novel agent for imaging and ultrasound guided drug delivery. In this study, we show that oxygen nanobubbles (ONB) can be propelled (up to 40 mm/s) and precisely guided in vivo to the tumor by an ultrasound beam. Nanobubble velocity can be controlled by altering the power of the ultrasound Doppler beam, while nanobubble direction can be adjusted to different desired angles by altering the angle of the beam ...
Our laboratory has a long-standing interest in using computation to simulate dynamic biological processes for the purpose of facilitating in vitro to in vivo and preclinical to clinical translations. We are particularly interested in developing computational paradigms for designing maximally effective clinical treatments. An example is our work in intravesical bladder cancer treatment, wherein computer simulations based on mathematical models of drug transport and tissue pharmacokinetics were done to identify the treatment conditions that would significantly improve treatment efficacy (28). The optimized treatment was tested in a randomized phase III trial; the results (19% improvement in recurrence-free rate) are identical to the model predictions (18-20% improvement; refs. 29, 30).. For intravesical therapy in bladder cancer, wherein the drug solution is instilled directly into the urinary bladder, the mathematical models depict the drug partitioning from urine into bladder tissues and the ...
According to our present knowledge the surgical intervention in the treatment of bladder cancer is essential, but some non-surgical treatment methods play an indispensable role as well. Superfi cial (non-muscle-invasive) form of bladder cancer can be treated by intravesical chemotherapy or BCG instillation, radiotherapy; the muscle-invasive forms of this tumour (≥pT2a) need neoadjuvant, adjuvant chemotherapy, radiotherapy or radio-chemotherapy. In case of metastatic disease (or locally advanced, recurrent disease) the treatment regimen consist of chemotherapy (given as fi rst line or second line), palliative radiotherapy, interventional methods, radio-isotope therapy and symptoms relief drugs. We present each of the therapeutic modalities and their indications category based on the ESMO and NCCN guidelines.. ...
43. Tingsheng Lin, Xiaozhi Zhao, Yifan Zhang, Huibo Lian, Junlong Zhuang, Qing Zhang, Wei Chen, Wei Wang, Guangxiang Liu, Suhan Guo, Jinhui Wu,*, Yiqiao Hu,* and Hongqian Guo* Floating Hydrogel with Self-Generating Micro-Bubbles for Intravesical Instillation Materials 2016, 9, 1005 ...
Treatment options for an inflamed bladder include bladder instillation, bladder distention, surgery and nerve stimulation, according to WebMD. Medications are also used to help treat the...
Anyone? Discount vendors seem to be out of stock and prices are rising. New brands (Manna, Theracyn), etc. Any info on what we should be buying and where? I used to buy for 13 dollars, now they are anywhere from 22 to 28 dollars. Last, any information on a clinical trial for bladder instillation on humans? Some here have been using this for 5 years or more, it seems that the market for instillation would be substantial, I am curious as to why there is no information on a clinical trial.
Visit your health care provider for checks on your progress. This medicine may make you feel generally unwell. Contact your health care provider if your symptoms last more than 2 days or if they get worse. Call your health care provider right away if you have a severe or unusual symptom.. Infection can be spread to others through contact with this medicine. To prevent the spread of infection, follow your health care providers directions carefully after treatment.. Do not become pregnant while taking this medicine. There is a potential for serious side effects to an unborn child. Talk to your health care provider for more information. Do not breast-feed an infant while taking this medicine.. If you have sex while on this medicine, use a condom. Ask your health care provider how long you should use a condom.. ...
Visit your doctor for checks on your progress. This drug may make you feel generally unwell. Contact your doctor if your symptoms last more than 2 days or if they get worse. Call your doctor right away if you have a severe or unusual symptom.. Infection can be spread to others through contact with this medicine. To prevent the spread of infection follow your doctors directions carefully after treatment. For the first 6 hours after each treatment, sit down on the toilet to urinate. After urinating, add 2 cups of bleach to the toilet bowl and let set for 15 minutes before flushing. Wash your hands before and after using the restroom.. Drink water or other fluids as directed after treatment with this medicine.. Do not become pregnant while taking this medicine. Women should inform their doctor if they wish to become pregnant or think they might be pregnant. There is a potential for serious side effects to an unborn child. Talk to your health care professional or pharmacist for more information. Do ...
Este fármaco se administra mediante un catéter de infusión en la vejiga. Un proveedor de atención médica especialmente capacitado lo administra en un hospital o clínica. Le darán indicaciones que deberá seguir antes del tratamiento. Siga atentamente las indicaciones de su proveedor de atención médica.. Este medicamento contiene bacterias vivas. Es muy importante seguir estas indicaciones atentamente después del tratamiento para evitar que otras personas entren en contacto con su orina. Es posible que su proveedor de atención médica le dé indicaciones adicionales que deberá seguir. Intente retener este medicamento en su vejiga por 1 a 2 horas. Siga estas indicaciones la primera vez que vaya al baño y durante 6 horas después de la primera micción.. Lávese las manos antes de usar el baño. Después de orinar, lávese las manos y el área de los genitales. Use un sanitario y siéntese cuando vaya al baño. Esto ayuda a evitar que se salpique orina. No use baños públicos ni orine ...
Two general strategies have been used to target myelomonocytic cells in tumors: inhibition of recruitment and/or elimination (the latter achieved by direct killing) and reeducation (Fig. 3). The plasticity and flexibility of myelomonocytic cells (Hagemann et al., 2008; Mosser and Edwards, 2008) provides a basis for strategies aimed at "resetting" TAMs in an antitumor mode. Agents in this broad category include the classic Th1 cytokine IFNγ, which early on showed objective responses in minimal residual ovarian cancer (Colombo et al., 1992; Pujade-Lauraine et al., 1996); bacterial products, with intravesical BCG being part of the armamentarium in bladder cancer; TLR agonists (e.g., CpG oligonucleotides, which are undergoing preclinical and clinical evaluation [e.g., Iida et al., 2013]); and antibodies that activate via the CD40 molecule. A fully human CD40 agonist antibody CP-870,893 was administered in combination with gemcitabine chemotherapy to 21 patients with advanced pancreatic cancer, with ...
Immunohistochemical expression of P-glycoprotein in the rat urinary bladder and the effect of verapamil on intravesical chemotherapy (2001 ...
Bacillus Calmette-Guérin (BCG) is a live vaccine, which is given to treat early-stage bladder cancer and helps prevent the cancer from recurring. When the medication is put into your bladder it causes inflammation. This inflammation destroys tumors and cancerous cells, therefore helping to stop the cancer from growing and spreading
The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy. ...
Well, I had my first six BCG treatments done. Once a week for six weeks. I get a cysto in 3 months. So I ask my fellow BC survivors out there, what do you do...
Intravesical instillation of Bacillus Calmette-Guérin (BCG) is the treatment of choice for superficial bladder carcinoma. Complications of BCG therapy include local infections and disseminated BCG infection with multiple endorgan complications. We report a case of disseminated, post-treatment BCG infection that initially presented with granulomatous hepatitis and choroiditis. After successful anti-mycobacterial therapy and resolution of the hepatic and ocular abnormalities, the patient developed an acute upper gastrointestinal hemorrhage from an aortoduodenal fistula that required emergency surgery. The resection specimen revealed multifocal, non-caseating granulomas, indicating mycobacterial involvement. This case highlights the varied end organ complications of disseminated BCG infection, and the need for vigilance even in immuno-competent patients with a history of intravesical BCG treatment.
... This report studies Intravesical Bacillus Calmette in Global market, especially - Market research report and industry analysis - 10750434
Intravesical infusion is into the urinary bladder.. *intravitreal, through the eye. *Subcutaneous (under the skin).[22] This ... extra-amniotic administration, between the endometrium and fetal membranes. *nasal administration (through the nose) can be ... Administration through the gastrointestinal tract is sometimes termed enteral or enteric administration (literally meaning ' ... Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local ( ...
In 1959, thiotepa was registered with the Food and Drug Administration (FDA) as a drug therapy for several solid cancers. On ... Thiotepa is used as intravesical chemotherapy in bladder cancer. It may be used prophylactically to prevent seeding of tumor ... "Urgent, thioTEPA update" (PDF). Food and Drug Administration. Adienne Pharma & Biotech. 5 April 2011. Retrieved 25 November ... For intravesical use, thiotepa is given in 30 mg doses weekly, for four to six weeks. Efficacy in tumor control may reach 55 ...
Di Stasi SM, Riedl C (June 2009). "Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle ... April 2009). "Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the ... Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O (June 2009). "Intravesical hyperthermia and mitomycin-C for carcinoma ... page needed] Witjes JA, Hendricksen K (January 2008). "Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a ...
Intravesical drug administration is the delivery of pharmaceuticals to the urinary bladder through a catheter. This route of ... Consequently, direct administration through the fibrous tunic is common. This is made difficult due to the numerous defense ... With a 0.1-0.7 mm thick mucus layer, the oral cavity serves as an important route of administration for mucoadhesive dosages. ... With an active surface area of 160 cm2, the nasal cavity is another noteworthy route of mucoadhesive administration. Due to the ...
... total parenteral nutrition Intravesical infusion is into the urinary bladder. intravitreal, through the eye Subcutaneous (under ... Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local ( ... extra-amniotic administration, between the endometrium and fetal membranes nasal administration (through the nose) can be used ... Parenteral administration generally acts more rapidly than topical or enteral administration, with onset of action often ...
After administration of apaziquone directly into the urinary bladder (intravesically), the drug and its active metabolite were ... October 2006). "Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer". J. Urol. 176 (4 Pt 1 ... The U.S. Food and Drug Administration (FDA) has granted Fast Track review status to apaziquone for this indication. "UvA ...
It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory ... Food and Drug Administration News. The MQN Weekly Bulletin, Jan. 11, 2008 "Endo Pharmaceuticals launches VALSTAR for treating ...
... , literally "under the lip", from Latin, refers to the pharmacological route of administration by which ... Upper lip administration[edit]. Some drugs are inactive in the digestive tract, but this can be avoided if held between the ... Sublabial administration should not be confused with sublingual administration, which is under the tongue. The frenulum of the ... Retrieved from "https://en.wikipedia.org/w/index.php?title=Sublabial_administration&oldid=735203906" ...
Intravitreal is a route of administration of a drug or other substance, in which the substance[1] is delivered into the eye. ... Intravitreal administration of drugs is used to treat various conditions of the eye. ... Retrieved from "https://en.wikipedia.org/w/index.php?title=Intravitreal_administration&oldid=836379009" ...
... has certain advantages over oral administration. Being more direct, it is often faster,[quantify] and ... Sublingual (abbreviated SL), from the Latin for "under the tongue", refers to the pharmacological route of administration by ... Sublingual Drug Administration at the US National Library of Medicine Medical Subject Headings (MeSH) ... This may be a preferred method to simple oral administration, because MAO is known to oxidize many drugs (especially the ...
... (from Ancient Greek ἐπί, "on, upon" + dura mater) is a medical route of administration in which a drug ... Epidural administration. A freshly inserted lumbar epidural catheter. The site has been prepared with tincture of iodine, and ... This article is about the route of administration and anaesthetic technique. For the anatomical site, see Epidural space. For ... Techniques such as epidural analgesia and epidural anaesthesia employ this route of administration. The epidural route is ...
In certain cancers, administration of hormone agonists, such as progestogens may be therapeutically beneficial. Angiogenesis ... Contemporary methods for generating an immune response against tumours include intravesical BCG immunotherapy for superficial ... Other problems include route of administration, maintenance of stability and activity and targeting at the tumor vasculature. ... Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm Agrelo R, Cheng WH, ...
Concurrently the slow administration of intravenous diuretics such as furosemide can correct the sodium by diuresis, however ... The patient should be kept horizontal, as assuming the Trendelenburg position (head tilt down 20°) reduces the intra-vesical ...
"Filling in Wrinkles Safely". U.S. Food and Drug Administration. 2016-12-20. Wickens JM1, Alsaab HO2, Kesharwani P3, Bhise K2, ... Boucher, W. S.; Letourneau, R.; Huang, M.; Kempuraj, D.; Green, M.; Sant, G. R.; Theoharides, T. C. (2002). "Intravesical ... "Soft Tissue Fillers Approved by the Center for Devices and Radiological Health". U.S. Food and Drug Administration. 2015-07-27 ...
In case of oral administration this 'enzymatic barrier' is even more pronounced as an additional degradation caused by ... "Development of pre-activated α-cyclodextrin as a mucoadhesive excipient for intra-vesical drug delivery". Int. J. Pharm. 534 (1 ... Madgulkar, AR; Bhalekar, MR; Kadam, AA (2017). "Improvement of oral bioavailability of lopinavir without co-administration of ... "Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in ...
Its a fully funded Grant-in-Aid Institution of Department of Atomic Energy, which also oversees the administration of institute ... and the role of urinary cytokines in intravesical BCG therapy in superficial bladder cancer. The biology of HIV-2, the virus ...
... intravesical bacillus Calmette Guerin, intravesical resiniferatoxin), high-pressure and long-duration hydrodistention, and ... "Policy Interpretation Ruling Titles II and XVI: Evaluation of Interstitial Cystitis". Social Security Administration. Archived ... Tyagi P, Kashyap MP, Kawamorita N, Yoshizawa T, Chancellor M, Yoshimura N (January 2014). "Intravesical liposome and antisense ...
However, it is important to note an abscess is not always associated with incorrect administration, and it is one of the more ... Houghton, BB; Chalasani, V; Hayne, D; Grimison, P; Brown, CS; Patel, MI; Davis, ID; Stockler, MR (May 2013). "Intravesical ... Nonetheless, the buttock is an alternative site of administration because it provides better cosmetic outcomes. BCG vaccine ... Lamm DL, Blumenstein BA, Crawford ED (1991). "A randomized trial of intravesical doxorubicin and immunotherapy with bacille ...
Grotenhermen F (June 2001). "Harm Reduction Associated with Inhalation and Oral Administration of Cannabis and THC". Journal of ... September 2008). "Effect of intrapulmonary tetrahydrocannabinol administration in humans". Journal of Psychopharmacology. 22 (7 ... for the pulmonary administration of tetrahydrocannabinol". Journal of Pharmaceutical Sciences. 95 (6): 1308-17. doi:10.1002/jps ... Regulated US Food and Drug Administration nicotine replacement products may be safer than e-cigarettes,[31] but e-cigarettes ...
Administration of lipid-based formulations to minipigs in the fasted and fed state". Eur J Pharm Sci. 31 (1): 8-15. PMID ... Within the last years SMEDDS were also utilized for the oral administration of biologics. Due to ion pairing with appropriate ... Gibaud, S. P.; Attivi, D. (2012). "Microemulsions for oral administration and their therapeutic applications". Expert Opinion ... for oral administration containing medium and long chain triglycerides". Eur J Pharm Sci. 28 (3): 233-42. PMID 16650738. doi: ...
A new method of drug administration". Current Researches in Anesthesia and Analgesia. 26 (6): 221-230. PMID 18917536.. ... August 14, 2014: The U.S. Food and Drug Administration (FDA) approved the use of the PharmaJet Stratis 0.5ml Needle-free Jet ... Warren, J; Ziherl, FA; Kish, AW; Ziherl, LA (1955). "Large-scale administration of vaccines by means of an automatic jet ... Needle-free Injector Receives WHO PQS Certification as a Pre-qualified Delivery Device for Vaccine Administration". ...
This would be used when administration by mouth was not possible because of the condition of the patient.[6] The Murphy drip ... Yung-Feng Hung, Automatically closed dripping apparatus for intravenous administration, US patent 5 234 414, filed 28 September ... administration of strong coffee through the rectum via a Murphy drip. When the attack got underway, Miller was joined by his ...
Oxygen helmets are used in hyperbaric oxygen chambers for oxygen administration.[1] They are transparent, lightweight plastic ... Oxygen helmets are often preferred for oxygen administration in hyperbaric oxygen chambers for children and patients that are ... and hyperbaric chamber and other patients who require administration of pure oxygen, such as carbon monoxide poisoning and ...
Many systems of administration employ a drip chamber, which prevents air from entering the blood stream (air embolism), and ... Compared with other routes of administration, such as oral medications, the intravenous route is the fastest way to deliver ... One reason veins are preferred over arteries for intravascular administration is because the flow will pass through the lungs ... The intravenous route of administration can be used for injections (with a syringe at higher pressures) or infusions (typically ...
Autoinjectors were originally developed for the rapid administration of nerve gas antidotes in kits like the Mark I NAAK. The ... Annex I: List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, ... The intramuscular route is preferred over subcutaneous administration because the latter may have delayed absorption.[3][4] ...
... begins with the contraction of the muscles attached to the rib cage; this causes an expansion in the chest cavity. Then takes place the onset of contraction of the diaphragm, which results in expansion of the intrapleural space and an increase in negative pressure according to Boyle's law. This negative pressure generates airflow because of the pressure difference between the atmosphere and alveolus. Air enters, inflating the lung through either the nose or the mouth into the pharynx (throat) and trachea before entering the alveoli.[citation needed] Other muscles that can be involved in inhalation include:[2] ...
Intravesical administration of drugs directly into the bladder allows a high concentration of medication to reach the target ... Intravesical Treatments: Intravesical drug instillations are second-line options per the AUA guidelines and consist of DMSO, ... Intravesical lidocaine with heparin and/or sodium bicarbonate may be used for those who have acute episodes of severe bladder ... DMSO is the only drug approved by the FDA for intravesical drug instillation.3 It is thought to provide relief by having anti- ...
negative urine pregnancy test on the day of treatment prior to the administration of study medication for females of ... 12 conclusion pregnancy outcomes appear good following treatment for interstitial cystitis with 1 course of intravesical dmso. ...
... BJU Int. 2004 Jun; ... Patients and methods: Forty women (mean age 35 years) with a history of recurrent UTI received intravesical instillations of HA ...
Subjects who cannot tolerate intravesical dosing or intravesical surgical manipulation. *Intravesical therapy within 6 weeks of ... Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. The safety and ... The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be ... The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be ...
1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory ... 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory ... Phase 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG ... Subjects who have a complete response to treatment at Week 12 in Part 1 receive second regimen of intravesical administration ...
To evaluate the safety of intravesical administration of a second-generation ultrasound (US) contrast agent for the diagnosis ... Thus, ce-VUS with intravesical administration of the second-generation US contrast agent (SonoVue®) for vesicoureteral reflux ... Contrast-enhanced voiding urosonography with intravesical administration of a second-generation ultrasound contrast agent for ...
Phase II Trial of concurrent administration of intravesical BCG & Interferon in the treatment and prevention of recurrence of ...
Hexaminolevulinate Hydrochloride Intravesical Solution) may treat, uses, dosage, side effects, drug interactions, warnings, ... Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution is intended for intravesical administration only after ... malignant lesions may not fluoresce following Cysview (hexaminolevulinate hydrochloride intravesical solution) administration, ... administration and are removed following the Cysview (hexaminolevulinate hydrochloride intravesical solution) instillation. ...
At all intravesical doses, significant systemic absorption was seen. The T1/2 (±SD) for intravesical and i.v. administration of ... We have demonstrated a markedly prolonged half-life after intravesical administration when compared with i.v. administration. ... Intravesical Administration.. Animals (n = 6) were initially treated with 350 mg (n = 1) and 3.5 g (n = 1) of drug, and blood ... Serum gemcitabine levels after 350 mg (n = 2) of drug by i.v. (♦; X) administration and by intravesical (. , , ▪) ...
This case illustrates the fact that although intravesical administration of bacillus Calmette-Guerin is generally considered to ... diagnosed 5 years after intravesical treatment with bacillus Calmette-Guerin therapy for bladder cancer. An 83-year-old ... two transurethral resections for high-grade transitional cell carcinoma of the bladder and had received 12 intravesical ... Intravesical administration of BCG has proved to be an effective form of treatment for some stages of bladder cancer [4]. There ...
To describe a case of epididymo-orchitis that developed four years after treatment with intravesical bacillus Calmette-Guérin ( ... Administration, Intravesical. Aged. BCG Vaccine / adverse effects*, therapeutic use. Carcinoma, Transitional Cell / ... OBJECTIVE: To describe a case of epididymo-orchitis that developed four years after treatment with intravesical bacillus ...
Intravesical drug administration and urine recovery in mice. Mice were anesthetized by the i.p. administration of ketamine/ ... Induction of elevated serum IFN-γ by intravesical administration of IL-12 plus BCG. Mice were treated intravesically every ... Synergy of intravesical IL-12 with BCG in inducing urinary and serum IFN-γ. The ability of rIL-12 to synergize with BCG to ... Synergy of intravesical IL-12 with BCG in inducing urinary IFN-γ. Mice were treated intravesically every other day with either ...
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.. ...
Thanks to a member here, supporting his father, I decided to try intravesical gentamicin (iGM). I wear a condom style catheter ... Intravesical Administration of Ditropan. By kos20 in forum Care Replies: 5 Last Post: 01-14-2008, 11:23 PM ...
Intravesical infusion is into the urinary bladder.. *intravitreal, through the eye. *Subcutaneous (under the skin).[22] This ... extra-amniotic administration, between the endometrium and fetal membranes. *nasal administration (through the nose) can be ... Administration through the gastrointestinal tract is sometimes termed enteral or enteric administration (literally meaning ... Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local ( ...
Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution is intended for intravesical administration only after ... 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dose 2.2 Reconstitution of Cysview 2.3 Bladder Instillation of Cysview 2.4 Use of ... DOSAGE AND ADMINISTRATION Training in blue light cystoscopy with the Karl Storz D-Light C PDD system is essential prior to the ... Systemic absorption following administration of Cysview is expected to be minimal [see Clinical Pharmacology (12.3)]. The lack ...
Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug Administration. Empty * Print ... To compare the outcomes of intravesical injection of botulinum toxin A (BoNTA) with intravesical electromotive drug ... administration (EMDA) of BoNTA on urinary incontinence secondary to neuropathic detrusor overactivity (NDO) in children with ...
Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent ... Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent ... Objectives: To compare the clinical effectiveness of the intravesical administration of combined hyaluronic acid and ... Interventions: Patients treated with either intravesical administration of HA+CS or standard of care (antimicrobial/ ...
Intravesical Administration: Patients with papillary carcinoma of the bladder are dehydrated for 8 to 12 hours prior to ... Deaths have occurred after intravesical administration, caused by bone-marrow depression from systemically absorbed drug. ... Intravenous Administration: Thiotepa may be given by rapid intravenous administration in doses of 0.3 to 0.4 mg/kg. Doses ... It is supplied as a non-pyrogenic, sterile Iyophilized powder for intravenous, intracavitary or intravesical administration, ...
ACETIC ACID INDUCED BLADDER PAIN RESPONSES IN RATS 24H AFTER INTRAVESICAL ADMINISTRATION. Ratna Ganabathi*, Pradeep Tyagi, ... INTRAVESICAL ELECTROMOTIVE DRUG ADMINISTRATION.... (EXPERIMENTAL STUDY). Tevlin K1, Korsunskaya I 2, Pushkar D2, 1. Moscow ... ELECTROMOTIVE DRUG ADMINISTRATION (EMDA).... OF PENTOSAN POLYSULFATE (PPS) IN THE THERAPY OF INTERSTITIAL CYSTITIS (IC). Loch A ... INTRAVESICAL RESINIFERATOXIN (RTX) IMPROVES.... LOWER URINARY TRACT SYMPTOMS (LUTS) AND URODYNAMIC PARAMETERS IN PATIENTS WITH ...
Intravesical medication. There is some evidence that introducing agents such as oxybutynin and atropine into the bladder will ... However this route of administration requires regular intermittent catheterisation (Fader et al, 2007). ... Fader, M. et al (2007) Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, ...
Joint Statement on Intravesical Administration of Therapeutic Medication SUNA and the American Urological Association (AUA) ... Read more about Joint Statement on Intravesical Administration of Therapeutic Medication. Consensus Statement on Advanced ... developed a joint Statement of Practice on Intravesical Administration of Therapeutic Medication. The purpose of the statement ... is to define the performance guidelines surrounding the instillation of intravesical cytotoxic, immunotherapeutic, and/or ...
Administration, Intravesical. The instillation or other administration of drugs into the bladder, usually to treat local ... Self Administration. Administration of a drug or chemical by the individual under the direction of a physician. It includes ... Administration, Topical. The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION ... Intravenous administration of the brand formulation of rocuronium bromide, currently used as a muscle relaxant, has been ...
Administration, Intravesical. The instillation or other administration of drugs into the bladder, usually to treat local ... A single intravesical instillation of Lactobacillus rhamnosus GG is safe in children and adults with neuropathic bladder: A ... A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer ... Surgical intervention combined with intravesical instillation of chemotherapeutics to clear residual cancer cells after ...
  • Oral pentosan polysulfate sodium (PPS) and intravesical dimethylsulfoxide (DMSO) are the only FDA-approved agents. (arhp.org)
  • MCNA was developed to be delivered as a sterile suspension for intravesical administration by urologists and urology nurses, following the same dosing paradigm as first-line BCG therapy, with the advantage that it can be prepared, handled and disposed of easily and safely. (prnewswire.com)
  • Intramuscular administration of drotaverine hydrochloride decreased the time to spontaneous micturition and decreased the incidence of urinary bladder catheterization in male patients who underwent orthopedic surgery under spinal anesthesia. (hindawi.com)
  • Recent data shows that a neuromuscular block (NMB) induced by administration of high doses of rocuronium improves surgical conditions in certain procedures. (bioportfolio.com)
  • Can be administered alone via any injectable route defined by the TGA, or can be administered acting as diluent for an injectable requiring reconstitution prior to administration. (pbs.gov.au)
  • This study was developed to determine whether the generation of free radicals, induced by ischemia followed by reperfusion in a model of chronic intravesical obstruction in rats, would lead to damage in the detrusor. (scielo.br)
  • Because of their involvement in the transport, handling, preparation, administration, or disposal of hazardous medications, health care workers across multiple settings are at risk for adverse health consequences from exposure to these drugs. (nursingcenter.com)
  • Endo holds exclusive global rights to develop and market Bioniche's patented formulation of Mycobacterial Cell Wall-DNA Complex (MCC), Urocidin ™ , being developed for the intravesical treatment of non-muscle invasive bladder cancer. (newswire.ca)